We are live on
!
Find out more
HM
HealthCor Management Portfolio holdings
AUM
$109M
1-Year Est. Return
10.64%
This Fund
S&P 500
This Quarter
Est. Return
-7.31%
1 Year Est. Return
+10.64%
3 Year Est. Return
+50.22%
5 Year Est. Return
+140.3%
10 Year Est. Return
–
AUM
$1.76B
AUM Growth
+$118M
(+7.2%)
Cap. Flow
+$242M
Cap. Flow
% of AUM
13.74%
Top 10 Holdings %
Top 10 Hldgs %
58.08%
Holding
55
New
13
Increased
19
Reduced
5
Closed
17
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
MNK
MALLINCKRODT PUBLIC LIMITED COMPANY
MNK
|
+$94.3M |
| 2 |
Quest Diagnostics
DGX
|
+$88.9M |
| 3 |
DexCom
DXCM
|
+$68.5M |
| 4 |
Edwards Lifesciences
EW
|
+$60.4M |
| 5 |
Zimmer Biomet
ZBH
|
+$59.8M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Eli Lilly
LLY
|
+$112M |
| 2 |
BXLT
BAXALTA INC COM STK (DE)
BXLT
|
+$105M |
| 3 |
BCR
CR Bard Inc.
BCR
|
+$83M |
| 4 |
Abbott
ABT
|
+$74.5M |
| 5 |
Vertex Pharmaceuticals
VRTX
|
+$59.4M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 78.19% |
| 2 | Financials | 3.18% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
Zoetis
ZTS
$32.4B
| $21.3M | 1.21% |
479,820
+473,820
| +7,897% | +$20.1M |
|
27
Bristol-Myers Squibb
BMY
$133B
| $19.9M | 1.13% |
+311,710
| New | +$19.7M |
|
|
ALXN
28
DELISTED
Alexion Pharmaceuticals
ALXN
| $19.9M | 1.13% |
142,920
+83,030
| +139% | +$12.2M |
|
|
CVRS
29
DELISTED
CORINDUS VASCULAR ROBOTICS, INC
CVRS
| $19.8M | 1.12% |
19,981,655
| – | – |
|
|
SYNH
30
DELISTED
Syneos Health, Inc. Class A Common Stock
SYNH
| $19.6M | 1.11% |
+475,000
| New | +$19.6M |
|
|
CELG
31
DELISTED
Celgene Corp
CELG
| $15.6M | 0.88% |
+155,660
| New | +$16M |
|
32
Cencora
COR
$60.6B
| $14.8M | 0.84% |
171,240
-287,900
| -63% | -$25.6M |
|
33
McKesson
MCK
$100B
| $12M | 0.68% |
+76,150
| New | +$12.3M |
|
34
Arbutus Biopharma
ABUS
$857M
| $9.21M | 0.52% |
2,229,300
+40,100
| +2% | +$143K |
|
|
SPNE
35
DELISTED
SeaSpine Holdings Corporation Common Stock
SPNE
| $9.01M | 0.51% |
615,100
+11,100
| +2% | +$154K |
|
36
Acadia Pharmaceuticals
ACAD
$4.43B
| $5.59M | 0.32% |
200,000
-386,564
| -66% | -$8.43M |
|
37
Natera
NTRA
$38.3B
| $2.73M | 0.15% |
286,800
+11,800
| +4% | +$99.9K |
|
|
HSTO
38
DELISTED
Histogen Inc. Common Stock
HSTO
| $2.24M | 0.13% |
5,229
+94
| +2% | +$36.3K |
|
39
AbbVie
ABBV
$443B
| – | – |
-188,600
| Closed | -$11.2M |
|
|
40
Abbott
ABT
$183B
| – | – |
-1,658,540
| Closed | -$74.5M |
|
41
Align Technology
ALGN
$12.1B
| – | – |
-8,000
| Closed | -$527K |
|
42
Amgen
AMGN
$208B
| – | – |
-2,250
| Closed | -$365K |
|
43
Biogen
BIIB
$30B
| – | – |
-47,090
| Closed | -$14.4M |
|
44
Brookdale Senior Living
BKD
$3.49B
| – | – |
-2,500,000
| Closed | -$46.1M |
|
45
Incyte
INCY
$24.2B
| – | – |
-322,030
| Closed | -$34.9M |
|
|
46
Eli Lilly
LLY
$1.02T
| – | – |
-1,325,000
| Closed | -$112M |
|
47
Merck
MRK
$322B
| – | – |
-246,741
| Closed | -$12.4M |
|
48
Pacira BioSciences
PCRX
$1.04B
| – | – |
-21,500
| Closed | -$1.65M |
|
49
Tandem Diabetes Care
TNDM
$1.34B
| – | – |
-19,511
| Closed | -$2.3M |
|
50
UnitedHealth
UNH
$376B
| – | – |
-8,150
| Closed | -$959K |
|
Similar funds
IA
EPC
TCMV
SI
HCWM
PC
RF
AWM
HealthCor Management's Q1 2016 Portfolio in Review
As of Q1 2016, HealthCor Management held 55 positions worth $1.76B, up 7.2% from $1.65B the previous quarter. Its ten largest holdings account for 58% of the portfolio.
HealthCor Management deployed $242M of net new capital in Q1 2016, opening 13 new positions and adding to 19 existing holdings. Its largest new stake was Aetna Inc: 500,000 shares worth $56.2M.
By sector, the portfolio is most concentrated in Healthcare at 78% of assets, up from 72% a quarter earlier, followed by Financials.
On the sell side, the largest reduction was CR Bard Inc., an estimated $83M trimmed.
- HealthCor Management's largest Q1 2016 buy was Aetna Inc: 500,000 shares worth $56.2M.
- HealthCor Management added most to MALLINCKRODT PUBLIC LIMITED COMPANY in Q1 2016, an estimated $94.3M increase.
- HealthCor Management's biggest Q1 2016 reduction was CR Bard Inc., cutting an estimated $83M.
- HealthCor Management fully exited Eli Lilly in Q1 2016, selling an estimated $112M.
- HealthCor Management's ten largest holdings make up 58% of its $1.76B portfolio in Q1 2016.
- HealthCor Management opened 13 new positions and closed 17 in Q1 2016.
- HealthCor Management's portfolio value rose 7.2% quarter-over-quarter to $1.76B.
Based on HealthCor Management's 13F filing for Q1 2016, filed 16 May 2016.